UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

December 1, 2017: By Joan McKenna

ExonateUK-based Exonate, an early stage company developing an eye drop treatment for wet AMD and diabetic macular edema, has formed a clinical advisory board of five ophthalmic experts.

Exonate’s preclinical compounds are designed to inhibit a protein kinase called SRPK1, which promotes production of vascular endothelial growth factor (VEGF), driving angiogenesis and retinal disease progression.

The five members of the advisory board are:

—Peter Adamson, PhD, head of ophthalmology research and development at Netherlands-based ProQR Therapeutics;

—Lloyd Paul Aiello, MD, PhD, professor of ophthalmology at Harvard Medical School and founding chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network;

—Peter Campochiaro, MD, professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute;

—Usha Chakravarthy, MD, professor of ophthalmology at Queen’s University Belfast, internationally known for research of the molecular mechanisms of AMD and diabetic retinopathy;

—Robyn Guymer, MBBS, PhD, professor of ophthalmology at Melbourne University, deputy director of the Centre for Eye Research Australia, and a senior retinal specialist at the Royal Victorian Eye and Ear Hospital.

In February, Exonate announced it had been awarded a £4.9 million seeding drug discovery award by the Wellcome Trust, a global charitable foundation, to continue development of its retinal candidates.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023